News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
69,960 Results
Type
Article (1939)
Company Profile (2)
Press Release (68019)
Section
Business (21480)
Career Advice (9)
Deals (4553)
Drug Development (8164)
FDA (1804)
Job Trends (801)
News (37042)
Policy (3561)
Tag
Academia (93)
Allergies (4)
Alliances (8138)
ALS (6)
Alzheimer's disease (123)
Antibody-drug conjugate (ADC) (13)
Approvals (1834)
Artificial intelligence (14)
Automation (1)
Bankruptcy (8)
Best Places to Work (586)
Biosimilars (22)
Biotechnology (5)
Bladder cancer (8)
Brain cancer (2)
Breast cancer (21)
Cancer (209)
Cardiovascular disease (5)
Career advice (9)
CAR-T (2)
Cell therapy (22)
Clinical research (7024)
Collaboration (93)
Compensation (9)
Complete response letters (2)
COVID-19 (185)
C-suite (16)
Cystic fibrosis (4)
Data (182)
Depression (1)
Diabetes (14)
Diagnostics (597)
Digital health (1)
Drug discovery (13)
Duchenne muscular dystrophy (12)
Earnings (7634)
Events (6992)
Executive appointments (50)
FDA (1951)
Featured Employer (1)
Fibrodysplasia Ossificans Progressiva (1)
Funding (59)
Gene editing (3)
Gene therapy (19)
GLP-1 (46)
Government (233)
Grass and pollen (1)
Guidances (4)
Healthcare (1078)
IgA nephropathy (4)
Immunology and inflammation (1)
Indications (3)
Infectious disease (192)
Inflammatory bowel disease (17)
Influenza (6)
Intellectual property (16)
IPO (1625)
Job creations (240)
Job search strategy (9)
Layoffs (6)
Legal (951)
Liver cancer (16)
Lung cancer (35)
Lymphoma (11)
Manufacturing (30)
MASH (7)
Medical device (1121)
Medtech (1122)
Mergers & acquisitions (3023)
Metabolic disorders (39)
Multiple sclerosis (8)
NASH (1)
Neurodegenerative disease (7)
Neuroscience (167)
NextGen: Class of 2025 (219)
Non-profit (61)
Northern California (136)
Obesity (16)
Opinion (1)
Ovarian cancer (10)
Pain (4)
Pancreatic cancer (8)
Parkinson's disease (15)
Partnered (2)
Patents (18)
Patient recruitment (7)
People (4973)
Pharmaceutical (3)
Phase I (1904)
Phase II (2941)
Phase III (2663)
Pipeline (122)
Postmarket research (241)
Preclinical (667)
Press Release (2)
Prostate cancer (6)
Radiopharmaceuticals (22)
Rare diseases (26)
Real estate (599)
Regulatory (2598)
Reports (6)
Research institute (92)
Schizophrenia (6)
Series A (15)
Series B (6)
Service/supplier (1)
Sickle cell disease (1)
Southern California (157)
Spinal muscular atrophy (4)
Startups (422)
Stomach cancer (1)
Supply chain (8)
United States (1295)
Vaccines (23)
Venture capitalists (2)
Weight loss (2)
Women's health (1)
Date
Today (3)
Last 7 days (52)
Last 30 days (221)
Last 365 days (2922)
2025 (829)
2024 (3257)
2023 (3821)
2022 (7021)
2021 (6379)
2020 (5876)
2019 (3866)
2018 (3013)
2017 (3562)
2016 (3172)
2015 (4031)
2014 (3020)
2013 (2600)
2012 (2775)
2011 (2902)
2010 (2663)
Location
Africa (79)
Alabama (1)
Arizona (8)
Asia (21378)
Australia (2433)
California (342)
Canada (224)
China (156)
Colorado (4)
Connecticut (14)
Delaware (4)
Europe (12450)
Florida (22)
Georgia (7)
Illinois (16)
India (11)
Indiana (4)
Japan (79)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (75)
Massachusetts (237)
Michigan (2)
Minnesota (27)
Missouri (3)
Nebraska (1)
Nevada (1)
New Jersey (195)
New York (145)
North Carolina (59)
Northern California (136)
Ohio (2)
Oregon (1)
Pennsylvania (53)
South America (106)
Southern California (157)
Tennessee (1)
Texas (28)
Utah (12)
Virginia (24)
Washington D.C. (2)
Washington State (16)
Wisconsin (6)
69,960 Results for "compugen ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen Ltd. today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
June 17, 2024
·
2 min read
Business
Compugen Appoints David Silberman as Chief Financial Officer
Compugen Ltd. today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day.
May 15, 2024
·
3 min read
Business
Compugen Reports First Quarter 2024 Results
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 20, 2024
·
11 min read
Compugen to Participate in Two Upcoming April 2024 Investor Conferences
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will participate in the following upcoming investor conferences in April.
April 3, 2024
·
2 min read
Business
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open.
May 6, 2024
·
2 min read
Drug Development
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd. today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca’s PD-1/TIGIT bispecific antibody.
May 30, 2024
·
7 min read
Business
Compugen Reports Fourth Quarter and Full Year 2023 Results
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported financial results for the fourth quarter and full year 2023 and provided a corporate update.
March 5, 2024
·
12 min read
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
Compugen Ltd. today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, on Monday, March 11, 2024 at 11:20 AM ET.
February 26, 2024
·
2 min read
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd. announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.
March 11, 2024
·
3 min read
Business
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.
February 15, 2024
·
5 min read
1 of 6,996
Next
